Alzheimer?s disease (AD) is the most common form of dementia but has no effective prevention or treatment. The brain proteome, ascertained in cerebrospinal fluid (CSF) have proven to be a rich source of information, reflecting A? plaques deposition, neurofibrillary tangles, neuronal injury and inflammation, and have helped the enrollment of participants in clinical trials. Still, additional non-invasive and cost-effective biomarkers are critical for the early detection, disease intervention and monitoring. Novel biomarkers may also help identify and characterize the additional aspects of AD, such as rate of progression and age at onset. Although genetic studies have focused on the identification of variants associated with risk through genome-wide association studies (GWAS) and whole genome and exome sequencing projects, the genetic factors modulating these additional aspects of AD are less investigated. The current proposal focuses on these understudied aspects of disease etiology, namely the role of common and rare genetic variation on quantitative diagnostic and prognostic endophenotypes of Alzheimer?s disease (AD). We will develop a unique resource ? the proteome ascertained in a plasma, CSF and brain for a large number of samples ? that will allow us to leverage unbiased approaches to reveal novel biomarkers and endophenotypes associated with AD and complex traits. We will utilize Mendelian Randomization to identify causal proteins involved in AD and extend our studies to other complex traits. We will use GWAS, exome-chip, whole-exome and whole-genome sequences to identify single variants, genes and pathways associated with plasma, cerebrospinal fluid (CSF) and brain protein levels of AD biomarkers.

Public Health Relevance

Alzheimer's disease (AD) is a common neurodegenerative disease with devastating personal, familial, societal and economical burdens, and there is currently no effective means of prevention or treatment. If successful, our research will reveal novel intermediate traits and genetic variants involved in AD and other complex traits, potentially leading to prospective therapeutic targets, and will also provide guidelines for accurate and practical assessments of AD status, which will be invaluable for evaluations of effectiveness of experimental treatments in clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG057777-02
Application #
9781459
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Miller, Marilyn
Project Start
2018-09-15
Project End
2023-05-31
Budget Start
2019-07-01
Budget End
2020-05-31
Support Year
2
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Washington University
Department
Psychiatry
Type
Schools of Medicine
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130